Nature Cancer

Article	Citations
Impaired immune responses in blood cancers improved by third COVID-19 vaccine dose	401
Hitting the target in HER2 mutant cancers	275
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	267
TRIM28-dependent developmental heterogeneity determines cancer susceptibility through distinct epigenetic states	264
Outcompeting neighbors for intestinal cancer initiation	225
MALAT1 protects dormant tumor cells from immune elimination	223
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	214
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells	210
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells	205
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity	202
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	199
Harnessing immune checkpoint trial data in pediatric cancer	195
γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors	186
The never-abating excitement for targeted therapies	179
Targeting network circuitry in glioma	163
Jeffrey W. Pollard (1950–2023)	155
Endothelium directs fat remodeling in cachexia	152
Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer	143
CRC malignancy continuum	140
Circumventing the roadblocks to targeting EGFR-driven cancers	135
Untangling the threads of immunotherapy research	134
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma	134
Outcomes of COVID-19 and risk factors in patients with cancer	132
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer	127
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	127

KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy	118
PARP11 interfer(on)es with CAR T cell efficacy	116
Gut decisions in CAR T cell therapy	116
A low-coverage liquid biopsy for lung cancer	108
The expanding palette of immunotherapy research	104
Diverse routes to melanoma metastasis and ICI resistance	104
Shooting for multiplexed pathology with Orion	103
Enhancing childhood cancer targetability	102
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	101
Alzheimer’s drug turns macrophages against cancer	101
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	100
Master kinases extracted from proteogenomic networks in glioblastoma drive cancer subtypes	91
Proteogenomic analysis of human pancreatic ductal adenocarcinoma	91
Cancer models for reverse and forward translation	90
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma	88
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting	87
Ovarian cancer through a multi-modal lens	86
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	86
An oncolytic circular RNA therapy	85
2-HG modulates glioma macrophages via Trp metabolism	82
Considering molecular alterations as pan-cancer tissue-agnostic targets	82
Improving long-term outcomes in pediatric low-grade glioma	81
An autologous antigen-agnostic dendritic cell therapy that forgoes antigen loading	81
The expanding success of T cell-engaging bispecific antibodies	80
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia	79
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	78
PRMT9 inhibition sparks immune responses in AML	75
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	74
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer	73
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	71
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study	70
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types	70
JAK inhibition shows two faces in prostate cancer	70
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer	70
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	69
Avoiding CAR-NK cell fratricide	66
Masking T cell engagers mitigates on-target off-tumor activity	65
Enhanced precision in immunotherapy	64
Associations of seven measures of biological age acceleration with frailty and all-cause mortality among adult survivors of childhood cancer in the St. Jude Lifetime Cohort	63
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	63
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS	62
The current landscape of immunotherapy for pediatric brain tumors	61
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	61
A new sophistication for breast cancer PDXs	61
Harnessing oncology real-world data with AI	61
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis	61
A platform for continuous learning in oncology	60
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial	60
cfDNA methylome profiling for detection and subtyping of small cell lung cancers	60
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	60

The moving target of cancer cell plasticity	59
Milestones in tumor vascularization and its therapeutic targeting	59
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer	59
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease	59
CD4+ T cells in cancer	57
The cGAS–STING pathway and cancer	57
A single inhibitor for all KRAS mutations	56
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity	56
A macrophage-activated abscopal effect	55
Challenges and opportunities in training cancer researchers	55
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	55
Immunological sex differences in glioblastoma	54
CD8+ T cell killing of MHC class I–deficient tumors	54
Two isoleucyl tRNAs that decode synonymous codons divergently regulate breast cancer metastatic growth by controlling translation of proliferation-regulating genes	51
CAR T cell therapy: looking back and looking forward	51
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer	51
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	51
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia	51
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment	50
The metabolic landscape of RAS-driven cancers from biology to therapy	49
Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	49
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	49
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	48
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma	48
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	48
c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation	47
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab	47
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma	46
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	46
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy	46
Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity	44
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities	43
Clinical and translational advances in ovarian cancer therapy	43
Centuries of genome instability and evolution in soft-shell clam, Mya arenaria, bivalve transmissible neoplasia	42
Overcoming therapy resistance in EGFR-mutant lung cancer	42
γδ T cells as critical anti-tumor immune effectors	41
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers	41
Publisher Correction: Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	40
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	40
Author Correction: Fatty acid synthesis is required for breast cancer brain metastasis	40
Author Correction: Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical tri	40
Author Correction: The immuno-oncological challenge of COVID-19	39
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	39
Breaking the performance ceiling for neoantigen immunogenicity prediction	39
Fatty acid synthesis is required for breast cancer brain metastasis	38
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology	38
The present and future of PI3K inhibitors for cancer therapy	38
Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers	38
Author Correction: Sonic hedgehog accelerates DNA replication to cause replication stress promoting cancer initiation in medulloblastoma	38
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	37
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	37
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer	36
2022 through the eyes of the editors	36
Five years of Nature Cancer	35
SULT1A1-dependent sulfonation of alkylators is a lineage-dependent vulnerability of liver cancers	35
Breaking frontiers with multidisciplinary cancer research	35
The 2022 generation	35
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer	35
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	34
Evolving cell states and oncogenic drivers during the progression of IDH-mutant gliomas	34
γδ T cells as unconventional targets of checkpoint blockade	34
CD4+ CAR T cells — more than helpers	33
Biocondensates fuel tumor immune evasion	33
The cornucopia of cancer biology	33
Advancing Cancer Therapy	32
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer	32
The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients	32
A community approach to the cancer-variant-interpretation bottleneck	32
A dormancy mechanism limits metastasis of early spreading cancer cells	31
Finding the positive in triple-negative breast cancer	31
Reaching your destination can require a diversion	31
High connectivity in gliomas affects cognition and survival	31
DePICting T cell–APC crosstalk in cancer	31
A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer	31
Bystander T cells in cancer immunology and therapy	30
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication	30
Spatial single-cell protein landscape reveals vimentinhigh macrophages as immune-suppressive in the microenvironment of hepatocellular carcinoma	30
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology	29
Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy	29
Lipids as mediators of cancer progression and metastasis	29

Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis	29
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response	29
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy	28
The meaning of impact	28
Communicating with respect	28
Beating cancer one carbon at a time	28
Pediatric cancer incidence in China	27
The year that was 2022	27
Defending health rights in a post-Roe world	27
Expanding the options for KRAS inhibition	27
IKAROS and MENIN in synergy in AML	27
Genomics guides targeted therapy	27
‘Self-damaging’ cells resist radiotherapy	26
Lung endothelium exploits susceptible tumor cell states to instruct metastatic latency	26
Fitting whole-genome sequencing analysis for metastasis	25
A PRC1–RNF2 knockout punch for cancer	25
Harnessing the microbiome to restore immunotherapy response	24
Inhibition of ERα signaling induces lineage plasticity in vivo	24
It’s a wrap for 2021!	24
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma	23
Publisher Correction: A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC	23
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer	23
Engineering-enhanced CAR T cells for improved cancer therapy	23
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues	23
Fatty acid synthesis enables brain metastasis	22
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs	22
Leveraging translational insights toward precision medicine approaches for brain metastases	22
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia	22
Dysregulation and therapeutic targeting of RNA splicing in cancer	22